http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4073928-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fb1de03102601dbebc9cc03992147de |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 1976-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1978-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23f751542c44fa3a784b0d31da0a9b41 |
| publicationDate | 1978-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4073928-A |
| titleOfInvention | Therapeutic treatment for viral regional ileitis infection |
| abstract | The administration internally to humans of 1-(β-hydroxyethyl)-2-methyl-5-nitromidazole, (metronidazole) in a dosage range for adult humans of about 31 to 2,500 mgs per 24 hour period, is an effective therapeutic treatment for viral regional ileitis. |
| priorityDate | 1974-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.